StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of EVOK opened at $5.54 on Friday. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $17.88. The business’s 50 day moving average price is $4.81 and its two-hundred day moving average price is $5.55. The firm has a market cap of $47.63 million, a PE ratio of -3.03 and a beta of 0.39.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The firm had revenue of $2.55 million for the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- ESG Stocks, What Investors Should Know
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What is the Hang Seng index?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Invest in the Best Canadian Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
